Vitamin D3

Correcting a vitamin D3 deficiency is not a psychedelic revelation or a stimulant rush. It is more like someone quietly turning the lights back on. People who have been deficient for months or years frequently describe the shift as "the fog lifting" or "finally feeling like myself again," particularly during winter months. Within 2-4 weeks of consistent supplementation at adequate doses (typically 4,000-5,000 IU daily), many report improved mood stability, better energy levels, clearer thinking, and a reduction in the vague, persistent fatigue that had become their baseline. The seasonal affective disorder connection is well-established: populations at higher latitudes show both lower D3 levels and higher rates of winter depression, and supplementation trials consistently show benefit.

There are important caveats. For people whose D3 levels are already sufficient (above 40-60 ng/mL), additional supplementation produces no subjective benefit and simply raises levels unnecessarily. At higher doses without K2 co-supplementation, some users report developing anxiety, restlessness, or heart palpitations, symptoms consistent with mild hypercalcemia from calcium being mobilized without adequate direction into bone. Community forums are full of reports linking D3-without-K2 to increased anxiety, and these reports align with the known physiology. Evening dosing can also disrupt sleep architecture, likely through D3's suppressive effect on melatonin synthesis; most experienced users recommend morning dosing for this reason.

Vitamin D3 is biologically inactive and must undergo two hydroxylation steps. First, in the liver, 25-hydroxylase converts it to 25-hydroxyvitamin D (calcidiol, the form measured in blood tests). Then in the kidneys (and locally in brain tissue), 1-alpha-hydroxylase converts it to 1,25-dihydroxyvitamin D (calcitriol), the active hormonal form.

Calcitriol binds to the vitamin D receptor (VDR), a nuclear receptor that heterodimerizes with retinoid X receptor (RXR) and regulates gene transcription. In the brain, VDR is expressed in the hippocampus, hypothalamus, prefrontal cortex, and substantia nigra. Calcitriol regulates expression of neurotrophic factors (NGF, GDNF, NT-3), modulates calcium homeostasis in neurons, promotes anti-inflammatory cytokine profiles, enhances serotonin synthesis by upregulating tryptophan hydroxylase 2 (TPH2), and promotes glutathione production.

Vitamin D also regulates the innate and adaptive immune system, promoting antimicrobial peptide production (cathelicidin, defensins) while preventing autoimmune overactivation.

The history of vitamin D begins with the understanding of rickets, a childhood bone disease that became epidemic during the Industrial Revolution as urban populations had limited sun exposure. In 1922, Edward Mellanby discovered that cod liver oil prevented rickets, and Elmer McCollum at Johns Hopkins identified the active factor, initially calling it vitamin D (having already named vitamins A, B, and C).

Adolf Windaus received the Nobel Prize in Chemistry in 1928 for his work on the structure of sterols and their connection to vitamins, including the identification that UV-irradiated ergosterol (vitamin D2) and 7-dehydrocholesterol (vitamin D3) were the dietary and endogenous forms, respectively.

The paradigm shift from viewing vitamin D as merely a bone vitamin to understanding it as a multi-system hormone came from research in the 1980s-2000s by Michael Holick, who demonstrated that VDR expression extends far beyond bones to virtually every tissue in the body. The connection between vitamin D and brain health has been established through epidemiological studies showing strong associations between D deficiency and depression, seasonal affective disorder, cognitive decline, and multiple sclerosis.